Citizens JMP lowered the firm’s price target on Savara (SVRA) to $9 from $10 and keeps an Outperform rating on the shares. Priority review for Molbreevi could provide a boost to shares in the near-term as management is laser-focused on a potential launch in early 2026, the analyst tells investors in a research note. The firm expects the FDA to accept the submission this month with a PDUFA date possibly by year-end.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara reports Q1 EPS (12c), consensus (13c)
- Savara announces encore presentations from Molgramostim Phase 3 IMPALA-2 trial
- Savara’s Strategic Advancements and Market Potential of Molbreevi: A Transformative Approach to aPAP Treatment
- Savara’s Strategic Positioning and Market Potential for Molbreevi in aPAP Treatment
- Savara reports Q4 EPS (13c), consensus (11c)